NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 50 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 446 → 449 locations
- Minor Study sites: 446 to 447
- Minor Study sites revised (446)
- Minor Study sites revised (446)
- Notable Eligibility criteria shortened, about 1 word
- Study sites: 445 to 446
- Secondary endpoints: details revised at 3 of 13 entries
Show 4 earlier versionsHide 4 earlier versions
- Minor Site details revised at 8 of 445 sitesv45
- Minor Study sites: 444 to 445
- Start date: Nov 7, 2024 to Nov 12, 2024
- Minor Study sites revised (444)v43
- Minor Study sites revised (444)v42
- Minor Trial sites reduced: 447 → 444 locationsv41
- Minor Trial sites expanded: 444 → 447 locationsv40
- Minor Study sites: 443 to 444v39
- Minor Study sites revised (443)v38
- Minor Trial sites expanded: 438 → 443 locationsv37
- Minor Trial sites expanded: 435 → 438 locationsv36
- Minor Trial sites expanded: 430 → 435 locationsv35
- Minor Interventions: Placebo matching survodutide (Drug), Survodutide (Drug) to Placebo matching survodutide (Combination Product), Survodutide (Combination Product)
- Study sites revised (430)
- Minor Study sites: 432 to 430
- Start date: Nov 12, 2024 to Nov 7, 2024
- Minor Study sites: 424 to 432v32
- Minor Study sites: 423 to 424v31
- Minor Study sites: 419 to 423v30
- Minor Study sites revised (419)v29
- Minor Study sites: 421 to 419v28
- Minor Study sites: 420 to 421v27
- Minor Study sites revised (420)v26
- Minor Study sites: 419 to 420v25
- Minor Study sites: 416 to 419
- Start date: Dec 2, 2024 to Nov 12, 2024
- Notable Eligibility criteria revised
- Study sites: 418 to 416
- Minor Study sites: 437 to 418v22
- Notable Eligibility criteria revised
- Study sites: 436 to 437
- Minor Study sites: 438 to 436v20
- Minor Site details revised at 8 of 438 sitesv19
- Minor Study sites: 434 to 438v18
- Minor Study sites: 435 to 434v17
- Minor Study sites: 429 to 435v16
- Minor Site details revised at 16 of 429 sitesv15
- Notable Eligibility criteria shortened, about 13 words
- Study sites: 361 to 429
- Secondary endpoints: 14 to 13
- Minor Study sites: 381 to 361
- Start date: Nov 12, 2024 to Dec 2, 2024
- Minor Study sites: 386 to 381v12
- Minor Study sites: 387 to 386v11
- Minor Study sites revised (387)v10
- Minor Study sites: 363 to 387v9
- Minor Study sites: 10 to 363v8
- Minor Study sites: 9 to 10v7
- Minor Study sites: 8 to 9v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 8
- Start date changed from estimate of Nov 15, 2024 to Nov 12, 2024
- Notable Start date: Oct 2, 2024 to Nov 15, 2024
- Trial status: Recruiting to Not Yet Recruiting
- Study sites: 4 to 0
- Minor Study sites: 1 to 4v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Oct 12, 2024 to Oct 2, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH
Timeframe: up to 4.5 years.
Secondary (13)
Key secondary endpoint: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Key secondary endpoint: Percentage change from baseline in body weight
Key secondary endpoint: Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c) (%) in participants with type 2 diabetes mellitus (T2DM) at baseline
Key secondary endpoint: Absolute change from baseline in liver stiffness (kPa) in FibroScan® vibration-controlled transient elastography (VCTE)
Percentage change from baseline in liver stiffness in FibroScan® VCTE
Show 8 moreShow less
Time to first occurrence of progression to CSPH
Time to first occurrence of any of the hepatic decompensation events (ascites, HE, or portal hypertension-related upper GI bleeding), or worsening of MELD score to ≥15
Occurrence of all-cause hospitalisation (first and recurrent)
Time to first occurrence of any of the adjudicated components of the composite endpoint 5-point major adverse cardiac event (5P-MACE)
Absolute changes from baseline in lipids (mg/dL)
Absolute change from baseline in aspartate aminotransferase (AST) (U/L)
Absolute change from baseline in alanine aminotransferase (ALT) (U/L)
Absolute change from baseline in liver stiffness (kPa) assessed by magnetic resonance elastography (MRE)
Arms and interventions
SurvodutideExperimental
PlaceboPlacebo comparator
Combination products: Survodutide, Placebo matching survodutide
Sites
449 sites in 37 countries
United States 127, Japan 55, China 50, United Kingdom 21, Germany 15, France 14, India 12, South Korea 10, Taiwan 10, Argentina 9, Brazil 9, Italy 9, Poland 9, Spain 9, Australia 8, Mexico 8, Turkey (Türkiye) 8, Bulgaria 7, Canada 6, Austria 5, Belgium 4, Hungary 4, Malaysia 4, New Zealand 4, Switzerland 4, Chile 3, Czechia 3, Netherlands 3, Puerto Rico 3, Singapore 3, Georgia 2, Jordan 2, Kazakhstan 2, Romania 2, Saudi Arabia 2, South Africa 2, Hong Kong 1